Blog

PaizaBio Pharma Insights Q&A-page-001(1)“China is in the midst of regulatory ‘shock and awe.’ PaizaBio provides multinational pharmaceutical companies with much needed on-the-ground insight and a clear path forward in China.”

October 4, 2016 I 2:30 PM I Pharma Forum Theater 1, Hall 2

It’s no secret that the global pharmaceutical industry is on the brink of transformational change. The reasons are many: blockbuster drugs are heading over the patent cliff, the biosimilar revolution, health systems’ increasing controls of drug formularies, and mounting government pricing pressure.

Despite the challenges, PaizaBio’s Chief Commercial Officer David Deere remains optimistic. The reason for David’s good cheer? China.

On Tuesday, October 4, 2016, David will reveal the basis for his optimism in a CPhI Worldwide Pharma Insights discussion entitled “Reformation of China’s Drug Regulatory Laws: Salvation for the Global Drug Industry.” The 2:30 p.m. discussion will be held in Pharma Forum Theater 1, Hall 2, and is limited to the first 100 guests.

Now we don’t want to give David’s thesis away, but rest assured it will focus on China’s rise to second largest pharmaceutical market in the world, the CFDA’s recent policy changes intended to thrust China into an active role in global pharma alongside multinational pharmaceutical companies, accelerate in-country drug innovation and commercialization, and expand access to affordable, modern medicines among its 1.4 billion citizens.

Certainly, that discussion is a lot to swallow, but David will also explore the best way to compete – and win – in the new China, and that involves playing by the new rules often with strategic partners who understand the intricacies and nuances of China’s pharmaceutical sectors.

David’s “Salvation” address at Pharma Insights is sure to open eyes – and minds – to the opportunities in China. We hope you will join us. For details on David’s discussion, download the attached flier.

 

Save